Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3317-3326

  Hsu, Hung Chih ^a,b   Chou, Wen Chi ^a,b   Shen, Wen Chi ^a,b   Wu, Chiao En ^a,b   Chen, Jen Shi ^a,b   Liau, Chi Ting ^a,b   Lin, Yung Chang ^a,b   Yang, Tsai Sheng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

5 fluorouracil; Colorectal liver metastasis; FOLFIRI; FOLFOX; Irinotecan; Leucovorin; Oxaliplatin; Postoperative chemotherapy; Synchronous metastasis

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

5-FLUOROURACIL; COLORECTAL LIVER METASTASIS; FOLFIRI; FOLFOX; IRINOTECAN; LEUCOVORIN; OXALIPLATIN; POSTOPERATIVE CHEMOTHERAPY; SYNCHRONOUS METASTASIS;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE CARE; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883285542     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
2. Jemal A, Siegel R, Xu J, and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
4. Heath 99 education source from Bureau of Health Promotion, Department of Health, Taiwan. Available at http:/health99. doh.gov.tw/Hot-News/h-NewsDetailN. aspx?TopIcNo=6615.
5. Ismaili N: Treatment of colorectal liver metastases World J Surg Oncol 9: 154-165, 2011.
6. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouche O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ and Rougier P: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911, 2008.
7. Nordlinger B, Sorbye H, Glimelius B, PostonGJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch- Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W and Gruenberger T: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371: 1007-1016, 2008.
8. Sharma S, Camci C and Jabbour N: Management of hepatic metastasis from colorectal cancers: An update. J Hepatobiliary Pancreat Surg 15: 570-580, 2008.
9. Portier G, Elias D, Bouche O, Rougier P, Bosset J, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F and Bedenne L: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24: 4976-4982, 2006.
10. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J and Rockette H: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies(C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355, 1999.
11. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP and Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22: 1797-1806, 2004.
12. Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M and de Gramont A: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 25: 3732-3738, 2007.
13. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O'Dwyer PJ and Benson AB 3rd: Combinedmodality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20: 1499-1505, 2002.
14. Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS and Neugut AI: Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 97: 1606-1612, 2007.
15. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C and Santoro A: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20(12): 1964-1970, 2009.
16. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA and Tschetter LK: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7(10): 1407-1418, 1989.
17. Jager E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Buschenfelde KH and Knuth A: RPMI regimen Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14(8): 2274-2279, 1996.
18. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U and Steinke B et al: Weekly therapy with folinic acid (FA) and high-dose 5- fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. a multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 5(3): 233-237, 1994.
19. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: IFL Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): 905-914, 2000.
20. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B and Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25(30): 4779-4786, 2007.
21. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22(2): 229-237, 2004.
22. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L and Hedrick E: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 26(21): 3523-3529, 2008.
23. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3): 176-181, 2003.
24. Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, Garden OJ, Blumgart LH and Fong Y: Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204: 753-761, 2007.
25. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Rague J, Serrano T and Fabregat J: Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 50: 478-488, 2007.
26. Cunningham D, Atkin W, Lenz HJ, Lynchn HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
27. Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK and Rha SY: Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology 81: 175-183, 2011.
28. Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K and Nagawa H: FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. Oncology 80: 84-91, 2011.
29. Shimada Y, Nakamura K, Sato A and Moriya Y, Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group: A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 39: 406-409, 2009.
30. Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH and Lin JK: Adjuvant oxaliplatinor irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis 25: 1243-1249, 2010.
31. Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R and Tekkis P: The tumour biology of synchronous and metachronous colorectal liver metastases: A systematic review. Clin Exp Metastasis 30(4): 457-470, 2012.
32. Bohanes P, Labonte MJ and Lenz HJ: A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 10(3): 157-164, 2011.
33. Jensen NF, Smith DH, Nygard SB, Romer MU, Nielsen KV and Brunner N: Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 47(3): 340-355, 2012.
34. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID and Punt CJ: Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs. metachronous metastases. Br J Cancer 103: 159-164, 2010.